Viquglip-DM-Forte
Description_Effects
Viquglip-DM-Forte is an advanced triple-action oral medication designed to manage type 2 diabetes mellitus. It contains a powerful combination of three antidiabetic agents: Dapagliflozin, Metformin, and Vildagliptin, which work synergistically to improve blood glucose control in adults. Dapagliflozin is an SGLT2 inhibitor that lowers blood sugar by promoting urinary glucose excretion, helping remove excess glucose from the body. Vildagliptin, a DPP-4 inhibitor, enhances the levels of natural incretin hormones, which stimulate insulin release and reduce glucose production in the liver, especially after meals. Metformin, a first-line biguanide agent, works by reducing hepatic glucose production, decreasing intestinal glucose absorption, and increasing insulin sensitivity in peripheral tissues. Together, these actions provide comprehensive glycemic control through different pathways—targeting insulin secretion, glucose reabsorption, and insulin sensitivity. Viquglip-DM-Forte not only helps maintain normal blood glucose levels but also supports the prevention of long-term diabetes complications like kidney damage, neuropathy, vision loss, heart disease, and stroke. For best results, this medicine should be taken consistently as prescribed, along with a balanced diet, regular exercise, and routine blood sugar monitoring. Continued use helps patients manage diabetes more effectively and live a healthier life.
